Risk of Developing Checkpoint Immune Pneumonitis and Its Effect on Overall Survival in Non-small Cell Lung Cancer Patients Previously Treated With Radiotherapy

Feliciano Barrón1, Roberto Sánchez1, Marisol Arroyo-Hernández1, Carolina Blanco2, Zyanya L. Zatarain-Barrón1, Rodrigo Catalán1, Maritza Ramos-Ramírez1, Andrés F. Cardona3,4,5, Diana Flores-Estrada1 and Oscar Arrieta1*

1 Thoracic Oncology Unit, Instituto Nacional de Cancerología, México City, Mexico, 2 Cancer Center, ABC Medical Center, México City, Mexico, 3 Clinical and Translational Oncology Group, Clínica del Country, Bogotá, Colombia, 4 Foundation for Clinical and Applied Cancer Research – FICMAC, Bogotá, Colombia, 5 Clinical Research and Biology Systems Department, Universidad el Bosque, Bogotá, Colombia

Introduction: Immune checkpoint inhibitor-related pneumonitis (ICIP) is a potentially life threatening immune-related adverse event (irAE), especially in non-small cell lung cancer (NSCLC) patients. Currently, the potential for increased irAE in patients who receive radiotherapy is scarcely known, although a connection between antitumor immune responses and irAEs has been suggested. In this study, we evaluated the development of ICIP in non-small cell lung cancer patients with prior radiotherapy, treated with immunotherapy in the second-line.

Methods: In this retrospective trial, we included patients treated with second-line immunotherapy at the National Cancer Institute in Mexico City from February 2015 to February 2018. Clinical, radiological and treatment variables were evaluated according to the presence of ICIP as defined by the Common Terminology Criteria for Adverse Events (4.0) in patients with or without a previous (> months) history of radiotherapy.

Results: Among 101 NSCLC patients who received treatment with ICIs, 22 patients (21.8%) were diagnosed with ICIP, of which 73% (16/22) had a history of radiotherapy (OR 6.04, 95% CI 2.03–18.0, p < 0.001). Median progression free survival and overall survival were similar in patients who developed ICIP compared with those who did not, however, patients who presented grade ≥ 2 ICIP had an increased risk of mortality (HR 2.54, 95% CI 1.20–5.34, p = 0.014).

Conclusion: In this real-world cohort of NSCLC patients treated with ICI, the history of prior radiotherapy was associated with increased risk for ICIP development. Unlike other irAEs, grade ≥ 2 ICIP is an independent prognostic factor for decreased survival in NSCLC patients.

Keywords: checkpoint immune therapy, pneumonitis, radiotherapy, NSCLC, lung cancer, immune related adverse effects
INTRODUCTION

Immune-checkpoint inhibitors anti-PD-1 and PD-L1 have changed the paradigm of treatment in several malignancies, including non-small cell lung cancer (NSCLC). Immunotherapy has demonstrated to improve overall survival (OS) and is now the standard of care for many solid tumors. The inhibition of the PD-1/PD-L1 axis can disrupt normal mechanisms of immune tolerance, resulting in increased immune activation in normal tissues; this in turn, can be associated with a unique set of adverse side effects, also known as immune-related adverse events (irAEs). Among them, immune checkpoint inhibitor-related pneumonitis (ICIP) has been reported as a potentially life-threatening irAE (1, 2).

Currently, a considerable subset of patients with locally advanced unresectable or metastatic NSCLC receive treatment with radiotherapy, alone or in combination with chemotherapy before being candidates to receive immunotherapy (3, 4). Moreover, radiotherapy has an important role in patients with brain metastases, as well as in radical treatment of patients with oligometastatic disease (5, 6).

Radiotherapy offers good local control of tumor growth; however, it also has multiple immune-modulatory effects. Radiation therapy induces DNA and membrane cellular damage, increasing reactive oxygen species (ROS) that activate transcription factors and signaling pathways modulating the immunophenotype and immunogenicity of tumor cells, restoring antitumor T-cell response in the tumor microenvironment, increasing tumor antigen release, while also improving antigen presentation and T-cell infiltration (7, 8). New evidence suggests that immunotherapy enhances antitumor immunogenicity of radiotherapy when used after local control with radiation (9).

Fractionated radiotherapy in combination with anti-PD-1/PD-L1 monoclonal antibodies was shown to generate effective CD8+ T-cell responses that improve local tumor control and long-term survival (10). Therefore, the risk of treatment-related symptoms might change with the advent of new treatment-combination modalities especially in real-world settings.

Immune checkpoint inhibitor-related pneumonitis is a challenging entity to diagnose, and currently there is no specific diagnostic test or symptoms which can outline ICIP patients. The most common scenarios with ICIP-like symptoms, such as infection and malignant lung infiltration, should always be initially ruled out. The risk of severe ICIP (grade 3 and 4) has been reported in randomized controlled trials more frequently in patients that receive monotherapy with CTLA-4 targeting agents (2–4%), followed by anti-PD-1 (1–3%) and anti-PD-L1 (0.4%) monoclonal antibodies (9, 11–13). Moreover, the rate increases (10%) when combinations with anti-PD-1/PD-L1 plus anti–CTLA-4 monoclonal antibodies are used (9), however, the incidence of ICIP may be underreported, as suggested by several retrospective studies of real-world data, in which the percentage of patients with ICIP is higher (10–20%) (14, 15).

The association with the history of radiotherapy and the risk of developing pneumonitis after treatment with ICIs has been scarcely described. We hypothesized that the risk of pneumonitis in patients that receive treatment with immunotherapy after radiotherapy increases compared with those who do not have a history of radiotherapy.

MATERIALS AND METHODS

Study Design and Patient Selection

We performed a retrospective cohort study to evaluate the incidence of ICIP on patients with advanced NSCLC who had previously undergone radiotherapy and were currently receiving ICIs in the second-line setting, as well as its effect in terms of survival outcomes. Patients who were treated at the National Cancer Institute in Mexico City between February 2013 and February 2018 were screened for inclusion. Patient demographic, clinical and pathological characteristics, immunotherapy treatment type, previous history of radiotherapy, irradiated region and doses (radiation doses were considered additive among different regions), previous chemotherapy and other outcomes were collected from electronic medical records. Every medical charts and image studies were evaluated by a multi-disciplinary team including at least: a medical oncologist, thoracic surgeon and a radiation oncologist. Infectious processes were excluded by utilizing blood cultures or sputum cultures, as needed by each patient; furthermore, every patient received clinical evaluation by an experienced medical oncologist prior to every treatment session.

Patients treated concomitantly with immunotherapy and radiotherapy were excluded.

ICIP Definition and Grading

All CT-scan were retrospectively reviewed. ICIP diagnosis was determined using a combination of clinical, radiological and biological tests to rule out differential diagnoses such as disease progression, infections, other comorbidities as well as radiation recall pneumonitis (pneumonitis limited to the radiation field). Pneumonitis toxicity grade was assessed according to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events version 4.0 (CTCAE v4.0). Immune checkpoint inhibitors therapy was suspended in all patients who presented with G2 or higher ICIP and who required treatment with high doses of corticosteroids.

Statistical Analysis

For descriptive purposes, continuous variables were summarized as arithmetic means and standard deviations (SDs), and categorical variables were expressed as frequencies and proportions. The χ2 and Fisher exact tests were used for evaluating the statistical significance between patient and treatment characteristics and the development of any grade of CIP. Progression free survival (PFS) was determined from the initiation of immunotherapy until progression of disease; OS was determined from initiation of immunotherapy until death by any cause or loss to follow-up. PFS and OS were analyzed by the Kaplan-Meier Method; risk factors for time to development of pneumonitis and univariate survival analysis were modeled by using a Cox proportional hazards model. All statistical tests were two-sided and p < 0.05.
was deemed to be statistically significant. SPSS software (version 22; SPSS; Chicago, IL, United States) was used for data analysis.

RESULTS

A total of 101 NSCLC patients treated with immune checkpoint inhibitors as second line were included for the analysis. Median age for all population was 61 years old (±12.3). Most patients were female (57.4%) and had a positive smoking history (53.5%). The most common histological subtype was adenocarcinoma (84.1%). PD-L1 status was known in 35.6% of patients (36/101 patients), of whom, 75% (27/36 patients) were positive. Other baseline characteristics of the cohort are presented on Table 1.

Regarding the treatment scheme, 41.6% (42/101) of patients were treated with nivolumab and 58.4% (59/101) with pembrolizumab as second-line of treatment. Among the included population, 40 patients (39.6%) received radiotherapy prior to ICI therapy; additionally, among radiotherapy-treated patients 17 (42.5%) received radiotherapy exclusively to the lung, 20 (50%) received radiotherapy to the vertebral column and three (7.5%) to mediastinal lymph nodes. The overall incidence of any-grade ICIP was 21.8% (22/101 patients). Incidence of ICIP in patients with history of radiotherapy was significantly higher compared with radiotherapy-naïve patients [40% vs. 9.8%; OR 6.11; 95% CI 2.13–17.52 (p < 0.001)]. In addition, doses greater than 60 Gy of radiation were associated with an increased risk of developing ICIP (OR 7.21; 95% CI 1.83–28.40) compared to patients who received less than 60-Gy (OR 5.35; 95% 1.56–18.42); however, this was not statistically significant.

Median time from ICI initiation to pneumonitis onset was 4.5 months (range 0.72–13.14 months). No association was found between line of treatment and the elapse time to ICIP development. The incidence of ICIP was similar between both ICI drugs (54.5% vs. 45.5% for nivolumab and pembrolizumab, respectively, p = 0.16).

Grade ≥ 2 ICIP developed in 12 patients (11.9%); and grade ≥ 3 in four patients (4%). Incidence of grade ≥ 2 ICIP was also higher in patients who received previous radiotherapy (22.5% vs. 4.9%). Remarkably, all patients that developed grade ≥ 3 pneumonitis had been previously treated with radiotherapy (Table 2). Despite the fact that tomography patterns can be superimposed, predominantly ground glass opacities, we can classify the damage based on the predominant injury; the tomographic pattern more frequently found was ground glass opacities, which was seen in 50% (12/22 patients), cryptogenic organizing pneumonia-like and pneumonitis not otherwise specified were found in 18.2% (4/22 patients), besides interstitial lung pattern, and hypersensitivity pneumonitis were reported (4.5% in both cases) (Figure 1).

Mean follow-up was of 9.22 months (range 0.22 – 44.2). Follow up was performed by scheduling medical visits ever 3-weeks. Patients that did not presented to scheduled visits during 2 months were contacted by a phone call; those patients that were unable to be contacted were censored from analysis.

In addition, a one, three, and six-months landmark analysis confirmed a trend toward a better OS at every point for the patients without ≥ grade 2 pneumonitis; with landmark analysis reaching statistical significance at 6 months [median OS of 23.7 (95% CI NR-NR) months for patients without pneumonitis ≥ grade 2 vs. 16.2 months (95% CI 6.8 – 25.6) for patients with pneumonitis ≥ grade 2; p 0.047]; landmark analysis at 1 month almost reached statistical significance for better OS in patients without pneumonitis ≥ grade 2 when compared with patients that developed pneumonitis ≥ grade 2 [median OS 22.4 months (95% CI 14.9 – 29.8) vs. 12.4 months (95% CI 5.5 – 19.4); p = 0.057], (Supplementary Figure 1).

A wide univariate analysis was performed to evaluate many base-line and treatment characteristics (Table 3). Furthermore, clinically relevant variables, and those that reached statistical significance at the univariate analysis were analyzed and adjusted through a multivariate model which is also presented at Table 3.

DISCUSSION

Lung toxicity presents with low frequency, but is often a serious treatment treatment-related complication in patients with NSCLC receiving ICI therapy. We retrospectively analyzed the frequency of ICIP and its correlation with prior radiotherapy in a cohort of patients with advanced NSCLC from a single medical center. Our results show that ICIP incidence in the real world scenario might be higher than reported in clinical trials (5, 7), with an all-grade ICIP incidence of 21.8% and a grade ≥ 3 ICIP of 4%, however, the frequency of ICIP increased when patients had a history of radiotherapy (40%).

Several studies have shown that the presence of irAEs is associated with a higher efficacy and improved overall survival in several solid tumors treated with ICIs, including NSCLC (16–18). Nonetheless, ICIP might be an exemption to this rule. As suggested by the publication of Suresh K. et al., ICIP increases mortality in patients with NSCLC, this observation is reported in patients with adenocarcinoma subtype histology, in whom risk of death increased proportionally with ICIP grade. These previous results support the findings in this study. Overall our data suggests that a history of radiotherapy increases the risk of ICIP, and increases mortality.

We observed an increased ICIP rate among patients with prior thoracic radiation, which supports the immunomodulatory effect of radiotherapy that converts an entirely or partially non-immunogenic tumor into an immunogenic one. Cell-death induced by radiotherapy generates molecular signals and inflammatory cytokines that promote the ability of dendritic cells to release antigens to T cells (19).

Different clinical trials have proven the benefit of using combination therapy. The PACIFIC trial demonstrated the
TABLE 1 | Demographic characteristics.

| Characteristic                      | Total (n = 101) |
|-------------------------------------|-----------------|
| **Sex**                             |                 |
| Female                              | 58 (57.4)       |
| Male                                | 43 (42.6)       |
| **Age (years)**                     |                 |
| Mean (SD)                           | 61.07 (±12.34)  |
| <60 years                           | 45 (44.6)       |
| ≥60 years                           | 56 (55.4)       |
| **History of smoking**              |                 |
| Never                               | 47 (46.5)       |
| Smoker                              | 54 (53.5)       |
| **Woodsmoke exposure**              |                 |
| No                                  | 78 (77.2)       |
| Yes                                 | 23 (22.8)       |
| **ECOG**                            |                 |
| 0                                   | 10 (9.9)        |
| 1                                   | 88 (87.1)       |
| ≥2                                  | 3 (3)           |
| **Stage**                           |                 |
| III                                 | 11 (10.9)       |
| IV                                  | 90 (89.1)       |
| **Histology**                       |                 |
| Adenocarcinoma                      | 85 (84.1)       |
| Squamous                            | 11 (10.9)       |
| Adenosquamous                       | 5 (5)           |
| **CNS Metastases**                  |                 |
| Yes                                 | 31 (30.7)       |
| No                                  | 70 (69.3)       |
| **EGFR mutation**                   |                 |
| Positive                            | 16 (15.8)       |
| Negative                            | 76 (75.2)       |
| Undetermined                        | 9 (8.9)         |
| **ALK mutation**                    |                 |
| Positive                            | 0 (0)           |
| Negative                            | 88 (87.1)       |
| Undetermined                        | 13 (12.9)       |
| **KRAS mutation**                   |                 |
| Positive                            | 0 (0)           |
| Negative                            | 34 (33.7)       |
| Undetermined                        | 67 (66.3)       |
| **PDL-1 status**                    |                 |
| Positive                            | 27 (26.7)       |
| Negative                            | 9 (8.9)         |
| Undetermined                        | 65 (64.4)       |
| **First-line therapy**              |                 |
| Platinum + Taxane                   | 39 (38.6)       |
| Platinum + Pemetrexed               | 34 (33.7)       |
| Platinum + Gemcitabine              | 6 (5.9)         |
| EGFR TKI                            | 14 (13.9)       |
| Other                               | 8 (7.9)         |
| **Immunotherapy**                   |                 |
| Nivolumab                           | 42 (41.6)       |
| Pembrolizumab                       | 59 (58.4)       |

(Continued)

advantage of using combined treatment modalities with chemoradiation and anti-PD-L1 (durvalumab) compared with chemoradiation and placebo in patients with NSCLC. PFS was 16.8 months in the durvalumab group versus 5.6 months in the placebo group also with a higher response rate (28.4% vs. 16% p < 0.001). However, the combination treatment leads to an increased risk of any grade of pneumonitis as observed in both groups (33.9% vs. 24.8%), as well as represents the most frequent adverse event leading to treatment discontinuation. A secondary analysis from phase 1 KEYNOTE-001 evaluated disease control and pulmonary toxicity in 97 patients with NSCLC that received pembrolizumab (20). This analysis reported that 8% (2/24) of patients who received prior chest-radiotherapy developed ICIP, compared with 1% (1/73) of patients who had not received prior chest-radiotherapy. Similarly, our results show that the incidence of ICIP was higher in the sample of patients who received prior radiotherapy. The KEYNOTE subanalysis also showed that OS was longer in patients who received pembrolizumab and radiotherapy, and in those who received extracranial radiotherapy, compared with those who did not (HR 0.59 95% CI 0.36–0.96). This supports the possibility of an enhancing the effect of radiotherapy on the immune system by combining this with pembrolizumab. Patients with a history of thoracic radiation had an overall higher frequency of treatment-related pulmonary toxicity in 63% (15/24) compared with no-previous lung radiotherapy with 40% (29/73) p = 0.052 (20).

The ongoing PEMBRO-RT trial was randomized phase II study that evaluated the improvement in overall response rate (ORR) at 12 weeks in 76 patients with NSCLC receiving pembrolizumab with or without prior stereotactic body radiotherapy (SBRT). The ORR at 12 weeks was 18% in the control arm vs. 36% in the experimental arm (P = 0.07). Median progression-free survival was 1.9 months (95% CI, 1.7–6.9 months) vs. 6.6 months (95% CI, 4.0–14.6 months) (hazard ratio, 0.71; 95% CI, 0.42–1.18; P = 0.19), and median overall survival was 7.6 months (95% CI, 6.0–13.9 months) vs. 15.9 months (95% CI, 7.1 months to not reached) (hazard ratio, 0.66; 95% CI, 0.37–1.18; P = 0.16), (21). Furthermore, patients who previously received thoracic radiotherapy were more likely to have any grade of pulmonary toxicity. These data highlight the role of radiotherapy in priming the immune response and thereby potentiating immune-mediated toxicity, also known as radiation recall syndrome. Radiation recall pneumonitis (RRP) is a specific subtype of radiation pneumonitis that occurs after the trigger of cytotoxic agents in a previous radiated lung. While the exact mechanism...
TABLE 2 | Characteristics among patients who experienced ICIP.

|                          | Pneumonitis (Any Grade) | Pneumonitis (Grade ≥ 2) | Pneumonitis (Grade ≥ 3) |
|--------------------------|-------------------------|-------------------------|-------------------------|
|                          | No pneumonitis | Pneumonitis | p | No pneumonitis | Pneumonitis | p | No pneumonitis | Pneumonitis | p |
| All patients (%)         |              |             |   |              |             |   |              |             |   |
| Female                   | 45 (77.6)    | 13 (22.4)   | 0.85 | 52 (89.7)    | 6 (10.3)    | 0.57 | 57 (98.3)    | 1 (1.7)     | 0.20 |
| Male                     | 34 (79.1)    | 9 (20.9)    |            | 37 (86)      | 6 (14)      |            | 40 (93)      | 3 (7)       |            |
| Age (years)              |              |             |   |              |             |   |              |             |   |
| <60 years                | 38 (84.4)    | 7 (15.6)    | 0.17 | 42 (93.3)    | 3 (6.7)     | 0.14 | 44 (97.8)    | 1 (2.2)     | 0.39 |
| ≥60 years                | 41 (73.2)    | 15 (26.8)   |            | 47 (83.9)    | 9 (16.1)    |            | 53 (94.6)    | 3 (5.4)     |            |
| History of smoking       |              |             |   |              |             |   |              |             |   |
| Never                    | 34 (72.3)    | 13 (27.7)   | 0.18 | 40 (85.1)    | 7 (14.9)    | 0.38 | 45 (95.7)    | 2 (4.3)     | 0.63 |
| Smoker                   | 45 (83.3)    | 9 (16.7)    |            | 49 (90.7)    | 5 (9.3)     |            | 52 (96.3)    | 2 (3.7)     |            |
| Woodsmoke Exposure       |              |             |   |              |             |   |              |             |   |
| No                       | 66 (86.8)    | 10 (13.2)   | 0.02 | 71 (93.4)    | 5 (6.6)     | <0.01 | 74 (97.4)    | 2 (2.6)     | 0.19 |
| Yes                      | 13 (56.5)    | 10 (43.5)   |            | 17 (73.9)    | 6 (26.1)    |            | 21 (91.3)    | 2 (8.7)     |            |
| ECOG                     |              |             |   |              |             |   |              |             |   |
| <2                       | 79 (80.6)    | 19 (19.4)   | <0.01 | 88 (89.8)    | 10 (10.2)   | <0.01 | 94 (95.9)    | 4 (4.1)     | 0.88 |
| ≥2                       | 0 (0)        | 3 (100)     |            | 1 (33.3)     | 2 (66.7)    |            | 3 (100)      | 0 (0)       |            |
| Stage                    |              |             |   |              |             |   |              |             |   |
| III                      | 7 (63.6)     | 4 (36.4)    | 0.21 | 9 (81.8)     | 2 (18.2)    | 0.49 | 11 (100)     | 0 (0)       | 0.62 |
| IV                       | 72 (80)      | 18 (20)     |            | 80 (88.9)    | 10 (11.1)   |            | 86 (95.6)    | 4 (4.4)     |            |
| Histology                |              |             |   |              |             |   |              |             |   |
| Adenocarcinoma           | 69 (81.2)    | 16 (18.8)   | 0.24 | 76 (89.4)    | 9 (10.6)    | 0.64 | 82 (96.5)    | 3 (3.5)     | 0.6  |
| Squamous                 | 7 (63.6)     | 4 (36.4)    |            | 9 (81.8)     | 2 (18.2)    |            | 10 (90.9)    | 1 (9.1)     |            |
| Adenosquamous            | 3 (60)       | 2 (40)      |            | 4 (80)       | 1 (20)      |            | 5 (100)      | 0 (0)       |            |
| EGFR mutation            |              |             |   |              |             |   |              |             |   |
| Positive                 | 13 (81.3)    | 3 (18.8)    | 0.66 | 13 (81.3)    | 3 (18.8)    | 0.65 | 16 (100)     | 0 (0)       | 0.39 |
| Negative                 | 58 (76.3)    | 18 (23.7)   |            | 68 (89.5)    | 8 (10.5)    |            | 73 (96.1)    | 3 (3.9)     |            |
| Undetermined             | 8 (80)       | 1 (20)      |            | 8 (88.9)     | 1 (21.1)    |            | 8 (88.9)     | 1 (11.1)    |            |
| PDL-1 status             |              |             |   |              |             |   |              |             |   |
| Positive                 | 19 (70.4)    | 8 (29.6)    | 0.17 | 22 (81.5)    | 5 (18.5)    | 0.29 | 26 (92.9)    | 2 (7.1)     | 0.53 |
| Negative                 | 9 (100)      | 0 (0)       |            | 9 (100)      | 0 (0)       |            | 10 (100)     | 0 (0)       |            |
| Undetermined             | 51 (78.5)    | 14 (21.5)   |            | 58 (89.2)    | 7 (10.8)    |            | 61 (96.8)    | 2 (3.2)     |            |
| Chemotherapy             |              |             |   |              |             |   |              |             |   |
| Platinum + Taxane        | 29 (85.3)    | 10 (25.6)   | 0.36 | 34 (87.2)    | 5 (12.8)    | 0.82 | 38 (97.4)    | 1 (2.6)     | 0.77 |
| Platinum + Pemetrexed    | 29 (85.3)    | 5 (14.7)    |            | 31 (91.2)    | 3 (8.8)     |            | 33 (97.1)    | 1 (2.9)     |            |
| Platinum + Gemicitabine  | 4 (66.7)     | 2 (33.3)    |            | 5 (83.3)     | 1 (16.7)    |            | 6 (100)      | 0 (0)       |            |
| Prior TKI treatment      |              |             |   |              |             |   |              |             |   |
| No                       | 65 (76.5)    | 20 (23.5)   | 0.44 | 75 (88.2)    | 10 (11.8)   | 0.79 | 81 (95.3)    | 4 (4.7)     | 0.40 |
| Yes                      | 12 (85.7)    | 2 (14.3)    |            | 12 (85.7)    | 2 (14.3)    |            | 14 (100)     | 0 (0)       |            |
| Immunotherapy Drug       |              |             |   |              |             |   |              |             |   |
| Nivolumab                | 30 (71.4)    | 12 (28.6)   | 0.16 | 34 (81)      | 8 (19)      | 0.6  | 40 (95.2)    | 2 (4.8)     | 0.72 |
| Pembrolizumab            | 49 (83.1)    | 10 (18.6)   |            | 55 (93.2)    | 4 (6.8)     |            | 57 (96.6)    | 2 (3.4)     |            |
| Radiotherapy             |              |             |   |              |             |   |              |             |   |
| Yes                      | 24 (60)      | 16 (40)     | <0.01 | 31 (77.5)    | 9 (22.5)    | <0.01 | 36 (90)      | 4 (10)      | <0.01 |
| No                       | 55 (90.2)    | 6 (9.8)     |            | 58 (95.1)    | 3 (4.9)     |            | 61 (100)     | 0 (0)       |            |

Bold text indicate analyzed characteristics and corresponding p values.

of RRP development is not yet well understood, the clinical, radiological and functional characteristics of the patients are similar as in radiation pneumonitis and the diagnosis is based on the premise of a previously radiated lung and the exposure to a triggering agent. The time range of RRP appearance since the triggering agent completion is wide (22–169 days) with a mean of 47 days (22). A diverse range of chemotherapeutic agents have been related to RRP, while only a few associations with molecular-targeted therapy have been reported (23).

As such, in this study we build on the previous evidence regarding the incidence of ICIP in NSCLC patients treated with ICIs and a history of radiation. The strength of this association is
considerable (OR 6.04), however, another previous study which reported 15 cases of ICIP among ICI treated patients had also identified a strong relationship between ICIP incidence and previous radiotherapy history. In this study, the authors report that 67% of patients with ICIP had undergone radiotherapy, nonetheless, the study included patients with a wide variety of
neoplasms, including melanoma, esophageal cancer and lung cancer, encompassing thus a heterogeneous sample. Despite this observation, the authors highlight that lung regions affected by the primary tumor, metastasis or radiotherapy had a significantly higher probability of ICIP compared with others, with an OR of 10.8 (24).

The relative high risk of pneumonitis among NSCLC patients may be explained because they are prone to develop drug-related lung toxic effects associated with several factors inherently related to the patient demographics, including their exposure to tobacco and underlying lung conditions (chronic obstructive pulmonary disease and pulmonary fibrosis). Existing tumor burden in the lung may also limit the lung tolerance to exogenous stress and injury. These underlying conditions may contribute to more serious clinical consequences from lung injury during pneumonitis. Drug-induced pneumonitis remains an exclusion diagnosis, and requires consideration of competing diagnoses, including infection and disease progression.

As it has been noted, there are huge differences among reported incidence of ICIP in patients with NSCLC that receive immunotherapy; the exact reason of such huge variations is not known, however, it might be related to ethnicity of studied population, awareness and recognition of ICPI, and study design. Lack of and specific diagnostic test for ICPI further complicates its diagnosis and reporting system. Therefore, we consider that it is important to evaluate the incidence and risk factors for ICIP in a real-world population with a future prospective study.

In the immunotherapy era, the anti-cancer therapy has been extended the reach of the immune system and many findings are extremely encouraging. However, the adverse effects of the novel combination therapies should be considered. Improvements in the treatment and understanding of the biology of pneumonitis

### TABLE 3 | Factors associated with overall survival.

|                    | No. (Events) | Median (95% CI) | p-value | HR (95% CI) | p-value | Adjusted HR (95% CI) | p-value |
|--------------------|--------------|-----------------|---------|-------------|---------|---------------------|---------|
| Overall            | 95 (42)      | 16.29 (10.8−21.7) |         |             |         | 1.56 (0.34−1.18)    | 0.15    |
| Sex                |              |                 |         |             |         |                     |         |
| Female             | 55 (20)      | 19.6 (15.3−23.9) | 0.18    | 0.66 (0.36−1.22) | 0.18    | 1.56 (0.34−1.18)    | 0.15    |
| Male               | 40 (22)      | 12.4 (10.6−21.4) | 0.18    | 0.66 (0.36−1.22) | 0.18    | 1.56 (0.34−1.18)    | 0.15    |
| Age (years)        |              |                 |         |             |         |                     |         |
| <60                | 42 (21)      | 16.2 (10.6−21.9) | 0.18    | 0.66 (0.36−1.22) | 0.18    | 1.56 (0.34−1.18)    | 0.15    |
| ≥60                | 53 (21)      | 19.6 (5.3−33.9)  | 0.62    | 0.85 (0.46−1.57) | 0.62    | 0.81 (0.44−1.50)    | 0.51    |
| Histology          |              |                 |         |             |         |                     |         |
| Adenocarcinoma     | 81 (35)      | 16.3 (12.9−19.7) | 0.64    | 1.21 (0.53−2.74) | 0.64    |                     |         |
| Other              | 14 (7)       | 7.3 (NA-NA)     |         |             |         |                     |         |
| Tobacco exposure   |              |                 |         |             |         |                     |         |
| No                 | 46 (19)      | 16.2 (10.0−22.5) | 0.72    | 0.94 (0.69−1.28) | 0.72    |                     |         |
| Yes                | 49 (23)      | 17.0 (5.6−28.5)  | 0.72    | 0.94 (0.69−1.28) | 0.72    |                     |         |
| Wood-smoke exposure|              |                 |         |             |         |                     |         |
| No                 | 44 (27)      | 16.1 (11.1−21.1) | 0.46    | 0.75 (0.36−1.59) | 0.45    |                     |         |
| Yes                | 40 (21)      | 19.9 (2.68−36)   | 0.46    | 0.75 (0.36−1.59) | 0.45    |                     |         |
| ECOG PS            |              |                 |         |             |         |                     |         |
| <2                 | 92 (39)      | 17.0 (10.9−23.1) | 0.67    | 1.11 (0.47−2.64) | 0.80    |                     |         |
| ≥2                 | 3 (5)        | 16.1 (2.01−30.90) | 0.67    | 1.11 (0.47−2.64) | 0.80    |                     |         |
| CNS Metastases     |              |                 |         |             |         |                     |         |
| No                 | 65 (29)      | 16.2 (10.7−21.6) | 0.99    | 0.99 (0.52−1.92) | 0.98    |                     |         |
| Yes                | 30 (13)      | 18.2 (10.9−21.7) | 0.99    | 0.99 (0.52−1.92) | 0.98    |                     |         |
| EGF R mutation     |              |                 |         |             |         |                     |         |
| Absent (wild-type) | 71 (29)      | 17.0 (13.2−20.8) | 0.21    | 1.24 (0.18−1.89) | 0.3      |                     |         |
| Present (EGF R mutated) | 15 (8)  | 12.4 (5.8−1.2) | 0.21    | 1.24 (0.18−1.89) | 0.3      |                     |         |
| Radiotherapy       |              |                 |         |             |         |                     |         |
| Yes                | 40 (19)      | 17.5 (10.4−23.7) | 0.930   | 0.97 (0.52−1.80) | 0.93    |                     |         |
| No                 | 55 (23)      | 16.2 (8.4−24.0)  | 0.930   | 0.97 (0.52−1.80) | 0.93    |                     |         |
| Pneumonitis        |              |                 |         |             |         |                     |         |
| No                 | 74 (31)      | 16.2 (9.5−23.0)  | 0.71    | 1.13 (0.57−2.26) | 0.71    |                     |         |
| Yes                | 22 (11)      | 16.1 (10.3−22.0) | 0.71    | 1.13 (0.57−2.26) | 0.71    |                     |         |
| Pneumonitis ≥ 2    |              |                 |         |             |         |                     |         |
| No                 | 84 (33)      | 22.3 (14.3−30.41)| 0.048   | 2.48 (1.18−5.23) | 0.028   | 2.54 (1.20−5.34)    | 0.014   |
| Yes                | 12 (9)       | 7.5 (0.51−14.5)  | 0.048   | 2.48 (1.18−5.23) | 0.028   | 2.54 (1.20−5.34)    | 0.014   |

Bold text indicate analyzed characteristics and corresponding p values.
are needed to optimize and maximize the therapeutic effect of checkpoint inhibitors in NSCLC patients.

**CONCLUSION**

Results from this study show that ICIP incidence is higher in real-world settings compared with clinical trials, with up to 21.8% of patients treated with ICIs diagnosed with ICIP. Our data might suggest that a prior history of radiotherapy could increase the risk of developing ICIP, which in turn might increase the mortality. However, prospective studies are needed to corroborate our results as well as to appropriately identify the true incidence and risk factors for developing ICIP. Beside this, the appropriate dose and modulation of radiotherapy, and the concomitant or sequential use of immunotherapy should be explored in clinical trials.

**DATA AVAILABILITY STATEMENT**

All datasets presented in this study are included in the article/Supplementary Material.

**ETHICS STATEMENT**

Ethical review and approval was not required for the study on human participants in accordance with the local legislation and institutional requirements. Written informed consent for participation was not required for this study in accordance with the national legislation and the institutional requirements.

**REFERENCES**

1. Friedman CF, Proverbs-Singh TA, Postow MA. Treatment of the immune-related adverse effects of immune checkpoint inhibitors: a review. *JAMA Oncol.* (2016) 2:1346–53. doi: 10.1001/jamaoncol.2016.1051
2. Postow MA, Sidlow R, Hellmann MD. Immune-related adverse events associated with immune checkpoint blockade. *N Engl J Med.* (2018) 378:158–68. doi: 10.1056/nejmra1703481
3. Torre-Bouscoulet L, Arroyo-Hernandez M, Martinez-Briseno D, Munoz-Montano WR, Geochico-Rangel L, Bacon-Fonseca L, et al. Longitudinal evaluation of lung function in patients with advanced non-small cell lung cancer treated with concurrent chemoradiation therapy. *Int J Radiat Oncol Biol Phys.* (2018) 101:910–8. doi: 10.1016/j.ijrobp.2018.04.014
4. Arrieta O, Gallardo-Rincon D, Villarreal-Garza C, Michel RM, Astorga-Ramos AM, Martinez-Barrera L, et al. High frequency of radiation pneumonitis in patients with locally advanced non-small cell lung cancer treated with concurrent radiotherapy and gemcitabine after induction with gemcitabine and carboplatin. *J Thorac Oncol.* (2009) 4:845–52. doi: 10.1097/jto.0b013e3181a97e17
5. Nishijima TF, Shachar SS, Nyrop KA, Muss HB. Safety and tolerability of PD-1/PD-L1 inhibitors compared with chemotherapy in patients with advanced cancer: a meta-analysis. *Oncologist.* (2017) 22:470–9. doi: 10.1634/theoncologist.2016-0419
6. Arrieta O, Barron F, Maldonado F, Cabrera L, Corona-Cruz JF, Blake M, et al. Radical consolidative treatment provides a clinical benefit and long-term survival in patients with synchronous oligometastatic non-small cell lung cancer: a phase II study. *Lung Cancer.* (2019) 130:67–75. doi: 10.1016/j.lungcan.2019.02.006
7. Demaria S, Golden EB, Formenti SC. Role of Local radiation therapy in cancer immunotherapy. *JAMA Oncol.* (2015) 1:1325–32. doi: 10.1001/jamaoncol.2015.2756
8. Walle T, Martinez Monge R, Cerwenka A, Ajona D, Meleiro L, Lecanda F. Radiation effects on antitumor immune responses: current perspectives and challenges. *Ther Adv Med Oncol.* (2018) 10:1758834017742575. doi: 10.1177/1758834017742575
9. Naidoo J, Wang X, Woo KM, Lyirboz T, Halpenny D, Cunningham J, et al. Pneumonitis in patients treated with anti-programmed death-1/programmed death ligand 1 therapy. *J Clin Oncol.* (2017) 35:709–17. doi: 10.1200/JCO.2016.68.2005
10. Patel SH, Rimner A, Cohen RB. Combining immunotherapy and radiation therapy for small cell lung cancer and thymic tumors. *Transl Lung Cancer Res.* (2017) e186–95. doi: 10.21037/tlcr.2017.03.04
11. De Velasco G, Je Y, Bosse D, Awad MM, Ott PA, Moreira RR, et al. Comprehensive Meta-analysis of key immune-related adverse events from CTLA-4 and PD-1/PD-L1 inhibitors in cancer patients. *Cancer Immunol Immunother.* (2017) 5:312–8. doi: 10.1158/2326-6066.CIR-16-0237
12. Khunger M, Rakshit S, Pasupuleti V, Hernandez AV, Mazzone P, Stevenson J, et al. Incidence of pneumonitis with use of programmed death 1 and Programmed death-ligand 1 inhibitors in non-small cell lung cancer: a systematic review and meta-analysis of trials. *Chest.* (2017) 152:271–81. doi: 10.1016/j.chest.2017.04.177
13. Nishino M, Giobbie-Hurder A, Hatabu H, Ramaiya NH, Hodi FS. Incidence of programmed cell death 1 inhibitor-related pneumonitis in patients with advanced cancer: a systematic review and meta-analysis, *JAMA Oncol.* (2016) 2:1607–16. doi: 10.1001/jamaoncol.2016.2453
14. Sears CR, Peikert T, Possick JD, Naidoo J, Nishino M, Patel SP, et al. Knowledge gaps and research priorities in immune checkpoint inhibitor-related pneumonitis. an official american thoracic society research statement. *Am J Respir Crit Care Med.* (2019) 200:e31–43. doi: 10.1164/rccm.201906-1202ST
15. Suresh K, Voong R, Zhong Q, Ettinger D, Marrone K, Kelly R, et al. Clinical, radiographic and bronchoalveolar lavage fluid characteristics of checkpoint inhibitor pneumonitis in non-small cell lung cancer patients receiving immune checkpoint immunotherapy. *Am Thorac Soc.* (2018) 197:A7758–A.
16. Menshawy A, Eltonob AA, Barkat SA, Ghanem A, Mniesy MM, Mohamed I, et al. Nivolumab mono-therapy or in combination with ipilimumab for...
metastatic melanoma: systematic review and meta-analysis of randomized-controlled trials. Melanoma Res. (2018) 28:371–9. doi: 10.1097/CMR.0000000000000467

17. Downey SG, Klapper JA, Smith FO, Yang JC, Sherry RM, Royal RE, et al. Prognostic factors related to clinical response in patients with metastatic melanoma treated by CTL-associated antigen-4 blockade. Clin Cancer Res. (2007) 13(22 Pt 1):6681–8. doi: 10.1158/1078-0432.CCR-07-0187

18. Aso M, Toi Y, Sugisaka J, Aiba T, Kawana S, Saito R, et al. Association between skin reaction and clinical benefit in patients treated with anti-programmed cell death 1 monotherapy for advanced non-small cell lung cancer. Oncologist. (2020) 25:e536–44. doi: 10.1634/theoncologist.2019-0550

19. Martinov T, Fife BT. Fractionated radiotherapy combined with PD-1 pathway blockade promotes CD8 T cell-mediated tumor clearance for the treatment of advanced malignancies. Ann Transl Med. (2016) 4:82.

20. Shaverdian N, Lisberg AE, Bornazyan K, Veruttipong D, Goldman JW, Formenti SC, et al. Previous radiotherapy and the clinical activity and toxicity of pembrolizumab in the treatment of non-small-cell lung cancer: a secondary analysis of the KEYNOTE-001 phase 1 trial. Lancet Oncol. (2017) 18:895–903. doi: 10.1016/S1470-2045(17)30380-7

21. Theelen WSME, Peulen HMU, Lalezari F, van der Noort E, Vries JF, Aerts JGJV, et al. Effect of pembrolizumab after stereotactic body radiotherapy vs pembrolizumab alone on tumor response in patients with advanced non-small cell lung cancer: results of the PEMBRO-RT Phase 2 randomized clinical trial. JAMA Oncol. (2019) 5:1276–82. doi: 10.1001/jamaoncol.2019.1478

22. Ding X, Ji W, Li J, Zhang X, Wang L. Radiation recall pneumonitis induced by chemotherapy after thoracic radiotherapy for lung cancer. Radiat Oncol. (2011) 6:24. doi: 10.1186/1748-717X-6-24

23. Shibaki R, Akamatsu H, Fujimoto M, Koh Y, Yamamoto N. Nivolumab induced radiation recall pneumonitis after two years of radiotherapy. Ann Oncol. (2017) 28:1404–5. doi: 10.1093/annonc/mdx115

24. Pozzessere C, Bouchaab H, Jumeau R, Letovanec I, Daccord C, Boughis J, et al. Relationship between pneumonitis induced by immune checkpoint inhibitors and the underlying parenchymal status: a retrospective study. ERJ Open Res. (2020) 6:00165–2019. doi: 10.1183/23120541.00165-2019

Conflict of Interest: OA reports personal fees from Pfizer, grants and personal fees from AstraZeneca and Boehringer Ingelheim, personal fees from Lilly, Merck, and Bristol Myers Squibb, grants and personal fees from Roche, outside the submitted work.

The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2020 Barrón, Sánchez, Arroyo-Hernández, Blanco, Zatarain-Barrón, Catalán, Ramos-Ramírez, Cardona, Flores-Estrada and Arrieta. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.